Abbreviations |
|
xxiii | |
Contributors |
|
xxxi | |
|
|
|
SECTION 1 Assessment of the patient with renal disease |
|
|
|
1 Epidemiology of kidney disease |
|
|
3 | (17) |
|
|
|
|
2 Clinical assessment of the patient with renal disease: overview |
|
|
20 | (2) |
|
|
3 Presentations of renal disease |
|
|
22 | (5) |
|
|
4 Kidney disease-focused history taking |
|
|
27 | (2) |
|
|
5 Kidney disease-focused features on examination |
|
|
29 | (6) |
|
|
|
35 | (9) |
|
|
7 Assessment of renal function |
|
|
44 | (18) |
|
|
|
|
62 | (4) |
|
|
|
9 Renal radiology: overview |
|
|
66 | (2) |
|
|
10 Ionizing radiation and radiation protection |
|
|
68 | (6) |
|
|
|
11 Plain radiography, excretion radiography, and contrast radiography |
|
|
74 | (8) |
|
|
|
|
82 | (7) |
|
|
|
89 | (12) |
|
|
|
|
101 | (8) |
|
|
|
15 Magnetic resonance imaging |
|
|
109 | (8) |
|
|
|
|
16 Radioisotopes in diagnostic imaging in nephrology |
|
|
117 | (10) |
|
|
|
17 Immunological investigation of the patient with renal disease |
|
|
127 | (15) |
|
|
|
|
142 | (19) |
|
|
|
|
19 Clinical trials: why and how in nephrology |
|
|
161 | (10) |
|
|
|
|
|
SECTION 2 The patient with fluid, electrolyte, and renal tubular disorders |
|
|
|
20 An overview of tubular function |
|
|
171 | (18) |
|
|
21 Sodium transport and balance: a key role for the distal nephron |
|
|
189 | (8) |
|
|
|
197 | (7) |
|
|
|
|
204 | (14) |
|
|
|
24 Renal acid-base homeostasis |
|
|
218 | (7) |
|
|
|
|
225 | (6) |
|
|
|
|
|
231 | (12) |
|
|
|
|
243 | (6) |
|
|
28 Approach to the patient with hyponatraemia |
|
|
249 | (12) |
|
|
|
29 Approach to the patient with hypernatraemia |
|
|
261 | (11) |
|
|
30 Approach to the patient with oedema |
|
|
272 | (10) |
|
|
|
31 Approach to the patient with salt-wasting tubulopathies |
|
|
282 | (9) |
|
|
|
32 Approach to the patient with polyuria |
|
|
291 | (8) |
|
|
33 Clinical use of diuretics |
|
|
299 | (24) |
|
|
|
34 Approach to the patient with hypo-/hyperkalaemia |
|
|
323 | (16) |
|
|
|
35 Approach to the patient with metabolic acidosis or alkalosis |
|
|
339 | (24) |
|
|
|
36 Approach to the patient with renal tubular acidosis |
|
|
363 | (9) |
|
|
37 Approach to the patient with hypercalcaemia |
|
|
372 | (6) |
|
|
|
38 Approach to the patient with hypocalcaemia |
|
|
378 | (6) |
|
|
|
39 Approach to the patient with hypo-/hyperphosphataemia |
|
|
384 | (13) |
|
|
|
|
|
40 Approach to the patient with hypomagnesaemia |
|
|
397 | (15) |
|
|
|
41 Approach to the patient with renal Fanconi syndrome, glycosuria, or aminoaciduria |
|
|
412 | (13) |
|
|
|
SECTION 3 The patient with glomerular disease |
|
|
|
42 The glomerulus and the concept of glomerulonephritis |
|
|
425 | (11) |
|
|
|
43 The renal glomerulus: the structural basis of ultrafiltration |
|
|
436 | (15) |
|
|
|
44 Function of the normal glomerulus |
|
|
451 | (8) |
|
|
|
|
45 Mechanisms of glomerular injury: overview |
|
|
459 | (4) |
|
|
46 The patient with haematuria |
|
|
463 | (6) |
|
|
|
47 Loin pain haematuria syndrome |
|
|
469 | (4) |
|
|
48 Nutcracker syndrome and phenomenon |
|
|
473 | (3) |
|
|
|
49 Exercise-related pseudonephritis |
|
|
476 | (2) |
|
|
|
478 | (7) |
|
|
|
51 Postural proteinuria (benign orthostatic proteinuria) |
|
|
485 | (2) |
|
|
|
487 | (9) |
|
|
|
|
53 Pathophysiology of oedema in nephrotic syndrome |
|
|
496 | (3) |
|
|
|
54 Idiopathic nephrotic syndrome: overview |
|
|
499 | (2) |
|
|
|
55 Minimal change disease: clinical features and diagnosis |
|
|
501 | (5) |
|
|
|
56 Minimal change disease: treatment and outcome |
|
|
506 | (9) |
|
|
|
57 Primary focal segmental glomerulosclerosis: clinical features and diagnosis |
|
|
515 | (10) |
|
|
|
58 Primary focal segmental glomerulosclerosis: treatment and outcome |
|
|
525 | (8) |
|
|
|
59 Pathogenesis of proteinuria in minimal change disease and focal segmental glomerulosclerosis |
|
|
533 | (4) |
|
|
|
60 Membranous glomerulonephritis: overview |
|
|
537 | (2) |
|
|
|
61 Membranous glomerulonephritis: clinical features and diagnosis |
|
|
539 | (5) |
|
|
|
62 Membranous glomerulonephritis: treatment and outcome |
|
|
544 | (13) |
|
|
|
63 Secondary membranous glomerulonephritis |
|
|
557 | (3) |
|
|
|
64 Membranous glomerulonephritis: pathogenesis |
|
|
560 | (5) |
|
|
|
65 Immunoglobulin A nephropathy: overview |
|
|
565 | (1) |
|
|
|
66 Immunoglobulin A nephropathy: clinical features |
|
|
566 | (6) |
|
|
|
67 Immunoglobulin A nephropathy: diagnosis |
|
|
572 | (5) |
|
|
|
68 Immunoglobulin A nephropathy: treatment and outcome |
|
|
577 | (9) |
|
|
|
69 Immunoglobulin A nephropathy: pathogenesis |
|
|
586 | (6) |
|
|
|
70 Crescentic (rapidly progressive) glomerulonephritis |
|
|
592 | (6) |
|
|
71 Antiglomerular basement membrane disease: overview |
|
|
598 | (1) |
|
|
|
|
72 Antiglomerular basement membrane disease: clinical features and diagnosis |
|
|
599 | (7) |
|
|
|
|
73 Antiglomerular basement membrane disease: treatment and outcome |
|
|
606 | (3) |
|
|
|
|
74 Antiglomerular basement membrane disease: pathogenesis |
|
|
609 | (10) |
|
|
|
|
75 Alport post-transplant antiglomerular basement membrane disease |
|
|
619 | (2) |
|
|
|
|
76 Post-infectious glomerulonephritis: overview |
|
|
621 | (2) |
|
Bernardo Rodriguez-Iturbe |
|
|
|
77 Post-streptococcal glomerulonephritis |
|
|
623 | (10) |
|
Bernardo Rodriguez-Iturbe |
|
|
|
78 Immunoglobulin A-dominant post-infectious glomerulonephritis |
|
|
633 | (3) |
|
Bernardo Rodriguez-Iturbe |
|
|
|
79 Glomerulonephritis associated with endocarditis, deep-seated infections, and shunt nephritis |
|
|
636 | (5) |
|
Bernardo Rodriguez-Iturbe |
|
|
|
80 Membranoproliferative glomerulonephritis and C3 glomerulopathy |
|
|
641 | (8) |
|
|
|
81 Fibrillary and immunotactoid glomerulopathy |
|
|
649 | (7) |
|
|
|
|
82 Drug-induced and toxic glomerulopathies |
|
|
656 | (13) |
|
|
|
SECTION 4 The patient with interstitial disease |
|
|
|
83 Acute tubulointerstitial nephritis: overview |
|
|
669 | (9) |
|
|
84 Drug-induced acute tubulointerstitial nephritis |
|
|
678 | (9) |
|
|
|
85 Other toxic acute tubulointerstitial nephritis |
|
|
687 | (3) |
|
|
|
86 Chronic tubulointerstitial nephritis: overview |
|
|
690 | (5) |
|
|
|
|
87 Drug-induced chronic tubulointerstitial nephritis |
|
|
695 | (7) |
|
|
|
88 Heavy metal-induced tubulointerstitial nephritis |
|
|
702 | (7) |
|
|
|
|
89 Aristolochic acid nephropathy caused by ingestion of herbal medicinal products |
|
|
709 | (5) |
|
|
|
90 Balkan endemic nephropathy |
|
|
714 | (5) |
|
|
|
|
719 | (5) |
|
|
|
|
724 | (2) |
|
|
|
93 Immune-mediated tubulointerstitial nephritis |
|
|
726 | (17) |
|
|
|
SECTION 5 The patient with reduced renal function |
|
|
|
94 Chronic kidney disease: definition, classification, and approach to management |
|
|
743 | (12) |
|
|
|
|
95 Chronic kidney disease in the developed world |
|
|
755 | (7) |
|
|
|
96 Chronic kidney disease in developing countries |
|
|
762 | (5) |
|
|
|
97 Chronic kidney disease long-term outcomes: progression, death, cardiovascular disease, infections, and hospitalizations |
|
|
767 | (10) |
|
|
|
|
|
98 Cardiovascular disease and chronic kidney disease: overview |
|
|
777 | (3) |
|
|
99 Recommendations for management of high renal risk chronic kidney disease |
|
|
780 | (7) |
|
|
|
100 Hypertension as a cause of chronic kidney disease: what is the evidence? |
|
|
787 | (6) |
|
|
|
101 Diet and the progression of chronic kidney disease |
|
|
793 | (7) |
|
|
|
|
102 Lipid disorders of patients with chronic kidney disease |
|
|
800 | (7) |
|
|
|
103 Smoking in chronic kidney disease |
|
|
807 | (6) |
|
|
104 Analytical aspects of measurements and laboratory values in kidney disease |
|
|
813 | (11) |
|
|
|
105 Effect of lifestyle modifications on patients with chronic kidney disease |
|
|
824 | (6) |
|
|
|
|
|
106 Malnutrition, obesity, and undernutrition in chronic kidney disease |
|
|
830 | (7) |
|
|
|
|
|
107 Left ventricular hypertrophy in chronic kidney disease |
|
|
837 | (16) |
|
|
|
|
108 Sudden cardiac death in chronic kidney disease |
|
|
853 | (16) |
|
|
|
|
109 Epidemiology of calcium, phosphate, and parathyroid hormone disturbances in chronic kidney disease |
|
|
869 | (8) |
|
|
|
|
110 The role of inflammation in chronic kidney disease |
|
|
877 | (7) |
|
|
|
111 Vascular stiffness in chronic kidney disease: pathophysiology and implications |
|
|
884 | (11) |
|
|
|
112 Oxidative stress and its implications in chronic kidney disease |
|
|
895 | (8) |
|
|
113 Abnormal endothelial vasomotor and secretory function |
|
|
903 | (7) |
|
|
|
114 Endothelins and their antagonists in chronic kidney disease |
|
|
910 | (6) |
|
|
|
115 Chronic kidney disease-mineral and bone disorder: overview |
|
|
916 | (7) |
|
|
|
116 Imaging for detection of vascular disease in chronic kidney disease patients |
|
|
923 | (11) |
|
|
|
117 Pathophysiology of chronic kidney disease-mineral and bone disorder |
|
|
934 | (5) |
|
|
|
|
118 Management of chronic kidney disease-mineral and bone disorder |
|
|
939 | (8) |
|
|
|
|
119 Fibroblast growth factor 23, Klotho, and phosphorus metabolism in chronic kidney disease |
|
|
947 | (10) |
|
|
120 Vascular calcification |
|
|
957 | (13) |
|
|
|
|
|
121 Fractures in patients with chronic kidney disease |
|
|
970 | (6) |
|
|
|
122 Spectrum of bone pathologies in chronic kidney disease |
|
|
976 | (7) |
|
|
|
123 Clinical aspects and overview of renal anaemia |
|
|
983 | (8) |
|
|
124 Erythropoiesis-stimulating agents in chronic kidney disease |
|
|
991 | (7) |
|
|
125 Iron metabolism in chronic kidney disease |
|
|
998 | (12) |
|
|
|
126 Iron management in renal anaemia |
|
|
1010 | (6) |
|
|
127 Pleiotropic effects of vitamin D |
|
|
1016 | |
|
|
|
|
|
|
1028 | (921) |
|
|
|
129 The epidemiology of hepatitis viruses in chronic kidney disease |
|
|
1049 | (3) |
|
|
|
130 Gastroenterology and renal medicine |
|
|
1052 | (12) |
|
|
|
|
131 Cutaneous manifestations of end-stage renal disease |
|
|
1064 | (8) |
|
|
|
|
132 The patient with reduced renal function: endocrinology |
|
|
1072 | (19) |
|
|
|
|
1091 | (8) |
|
|
|
134 Health-related quality of life and the patient with chronic kidney disease |
|
|
1099 | (3) |
|
|
|
135 Coagulopathies in chronic kidney disease |
|
|
1102 | (3) |
|
|
|
|
136 Mechanisms of progression of chronic kidney disease: overview |
|
|
1105 | (2) |
|
|
137 Proteinuria as a direct cause of progression |
|
|
1107 | (5) |
|
|
138 Nephron numbers and hyperfiltration as drivers of progression |
|
|
1112 | (6) |
|
|
139 Podocyte loss as a common pathway to chronic kidney disease |
|
|
1118 | (8) |
|
|
140 Disordered scarring and failure of repair |
|
|
1126 | (10) |
|
|
141 Modality selection for renal replacement therapy |
|
|
1136 | (6) |
|
|
|
142 Patient education and involvement in pre-dialysis management |
|
|
1142 | (6) |
|
|
|
143 Preparation for renal replacement therapy |
|
|
1148 | (9) |
|
|
|
|
144 Choices and considerations for in-centre versus home-based renal replacement therapy |
|
|
1157 | (8) |
|
|
|
145 Conservative care in advanced chronic kidney disease |
|
|
1165 | (15) |
|
|
|
146 Palliative care in end-stage renal disease |
|
|
1180 | (7) |
|
|
|
|
147 Patient selection when resources are limited |
|
|
1187 | (5) |
|
|
|
148 Acidosis in chronic kidney disease |
|
|
1192 | (7) |
|
|
|
|
|
|
SECTION 6 The patient with another primary diagnosis |
|
|
|
149 The patient with diabetes mellitus |
|
|
1199 | (49) |
|
|
|
|
150 Kidney involvement in plasma cell dyscrasias |
|
|
1248 | (3) |
|
|
151 The patient with cryoglobulinaemia |
|
|
1251 | (13) |
|
|
|
152 The patient with amyloidosis |
|
|
1264 | (12) |
|
|
|
153 The patient with myeloma |
|
|
1276 | (16) |
|
|
|
154 Light-chain deposition disease |
|
|
1292 | (7) |
|
|
|
155 Other consequences from monoclonal immunoglobulins/fragments: membranoproliferative glomerulonephritis and acquired Fanconi syndrome |
|
|
1299 | (5) |
|
|
|
|
156 The patient with sarcoidosis |
|
|
1304 | (3) |
|
|
|
157 The patient with vasculitis: overview |
|
|
1307 | (8) |
|
|
158 The patient with vasculitis: pathogenesis |
|
|
1315 | (17) |
|
|
|
159 The patient with vasculitis: clinical aspects |
|
|
1332 | (12) |
|
|
160 The patient with vasculitis: treatment and outcome |
|
|
1344 | (12) |
|
|
|
161 The patient with systemic lupus erythematosus: overview and pathogenesis |
|
|
1356 | (9) |
|
|
|
162 The patient with systemic lupus erythematosus: clinical features, investigations, and diagnosis |
|
|
1365 | (15) |
|
|
|
|
163 The patient with systemic lupus erythematosus: treatment and outcome |
|
|
1380 | (9) |
|
|
164 The patient with antiphospholipid syndrome with or without lupus |
|
|
1389 | (6) |
|
|
|
165 The patient with scleroderma: systemic sclerosis |
|
|
1395 | (8) |
|
|
|
166 The patient with rheumatoid arthritis, mixed connective tissue disease, Sjogren syndrome, or polymyositis |
|
|
1403 | (10) |
|
|
|
|
167 The patient with sickle cell anaemia |
|
|
1413 | (11) |
|
|
|
168 The obese patient (metabolic syndrome) |
|
|
1424 | (9) |
|
|
|
|
169 The patient with hepatorenal syndrome |
|
|
1433 | (9) |
|
|
|
|
1442 | (8) |
|
|
|
1450 | (7) |
|
|
|
|
172 The patient with renal cell cancer |
|
|
1457 | (7) |
|
|
173 The patient with Wilms tumour |
|
|
1464 | (5) |
|
|
174 The patient with haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura |
|
|
1469 | (24) |
|
|
|
SECTION 7 The patient with urinary tract infection |
|
|
|
175 Urinary tract infection in the adult: overview |
|
|
1493 | (2) |
|
|
176 Infection of the lower urinary tract |
|
|
1495 | (11) |
|
|
|
177 Upper urinary tract infection |
|
|
1506 | (8) |
|
|
178 Complicated urinary tract infection |
|
|
1514 | (3) |
|
|
|
179 Urinary tract infection in a patient with a kidney transplant |
|
|
1517 | (3) |
|
|
180 Urinary tract infection in infancy and childhood |
|
|
1520 | (12) |
|
|
181 Schistosomiasis: the parasite and the host |
|
|
1532 | (6) |
|
|
182 Schistosomiasis: clinical impact |
|
|
1538 | (7) |
|
|
SECTION 8 The patient with infections causing renal disease |
|
|
|
|
1545 | (5) |
|
|
|
184 Leishmaniasis and trypanosomiasis |
|
|
1550 | (2) |
|
|
|
|
1552 | (8) |
|
|
|
|
1560 | (7) |
|
|
187 HIV and renal disease |
|
|
1567 | (9) |
|
|
|
188 Hantaviral infections |
|
|
1576 | (5) |
|
|
|
|
|
189 Dengue and other viral haemorrhagic fevers |
|
|
1581 | (3) |
|
|
|
190 Yellow fever, severe acute respiratory syndrome virus, and H1N1 influenza infections |
|
|
1584 | (3) |
|
|
|
1587 | (3) |
|
|
|
1590 | (2) |
|
|
|
1592 | (4) |
|
|
|
|
1596 | (6) |
|
|
|
1602 | (2) |
|
|
|
196 Mycobacterial infections: tuberculosis |
|
|
1604 | (16) |
|
|
|
|
197 Mycobacterial infections: leprosy and environmental mycobacteria |
|
|
1620 | (5) |
|
|
|
|
198 Renal involvement in other infections: diarrhoeal diseases, salmonella, melioidosis, and pregnancy |
|
|
1625 | (6) |
|
|
|
SECTION 9 The patient with urinary stone disease |
|
|
|
199 Epidemiology of nephrolithiasis |
|
|
1631 | (6) |
|
|
|
200 Approach to the patient with kidney stones |
|
|
1637 | (8) |
|
|
|
|
1645 | (16) |
|
|
|
|
1661 | (5) |
|
|
|
|
1666 | (5) |
|
|
|
204 Cell biology of nephrocalcinosis/nephrolithiasis |
|
|
1671 | (26) |
|
|
|
205 Medical management of nephrocalcinosis and nephrolithiasis |
|
|
1697 | (16) |
|
|
|
|
|
206 Imaging and interventional treatment: urolithiasis from the surgeon's point of view |
|
|
1713 | (12) |
|
|
|
SECTION 10 The patient with hypertension |
|
|
|
207 The structure and function of renal blood vessels |
|
|
1725 | (4) |
|
|
|
208 Regulation of vasomotor tone in the afferent and efferent arterioles |
|
|
1729 | (9) |
|
|
|
209 Tubuloglomerular feedback, renal autoregulation, and renal protection |
|
|
1738 | (4) |
|
|
|
210 The kidney and control of blood pressure |
|
|
1742 | (8) |
|
|
|
211 The effect of hypertension on renal vasculature and structure |
|
|
1750 | (10) |
|
|
|
|
212 Ischaemic nephropathy |
|
|
1760 | (6) |
|
|
|
|
|
213 Renal artery stenosis: clinical features and diagnosis |
|
|
1766 | (10) |
|
|
|
|
|
214 Renal artery stenosis: diagnosis |
|
|
1776 | (6) |
|
|
|
|
|
215 Renal artery stenosis: management and outcome |
|
|
1782 | (10) |
|
|
|
|
|
216 Malignant hypertension |
|
|
1792 | (7) |
|
|
|
217 Resistant hypertension |
|
|
1799 | (3) |
|
|
|
218 The hypertensive child |
|
|
1802 | (23) |
|
|
219 Treatment of hypertension in children |
|
|
1825 | (6) |
|
|
SECTION 11 The patient with acute kidney injury (and critical care nephrology) |
|
|
|
220 Definitions, classification, epidemiology, and risk factors of acute kidney injury |
|
|
1831 | (13) |
|
|
|
221 Pathophysiology of acute kidney injury |
|
|
1844 | (28) |
|
|
|
|
|
|
222 Clinical approach to the patient with acute kidney injury: diagnosis and differential diagnosis |
|
|
1872 | (15) |
|
|
|
|
223 The role of novel biomarkers in acute kidney injury |
|
|
1887 | (9) |
|
|
224 Prevention of acute kidney injury: overview |
|
|
1896 | (6) |
|
|
225 Prevention of acute kidney injury: non-pharmacological strategies |
|
|
1902 | (13) |
|
|
226 Prevention of acute kidney injury: pharmacological strategies |
|
|
1915 | (10) |
|
|
227 Prevention of acute kidney injury: drug- and nephrotoxin-induced acute kidney injury |
|
|
1925 | (8) |
|
|
228 Non-dialytic management of the patient with acute kidney injury |
|
|
1933 | (8) |
|
|
|
|
229 Fluid overload in acute kidney injury |
|
|
1941 | (4) |
|
|
|
|
230 Electrolyte and acid--base disorders in AKI |
|
|
1945 | (9) |
|
|
|
|
231 Coagulation disturbances in acute kidney injury |
|
|
1954 | (2) |
|
|
|
|
232 Renal replacement therapy in the patient with acute kidney injury: overview |
|
|
1956 | (6) |
|
|
|
233 Intermittent acute renal replacement therapy |
|
|
1962 | (13) |
|
|
234 Continuous renal replacement therapy |
|
|
1975 | (14) |
|
|
|
235 Peritoneal dialysis in acute kidney injury |
|
|
1989 | (9) |
|
|
236 Scoring systems in acute kidney injury patients |
|
|
1998 | (11) |
|
|
|
|
|
237 Overall outcomes of acute kidney injury |
|
|
2009 | (8) |
|
|
|
|
238 Renal outcomes of acute kidney injury |
|
|
2017 | (7) |
|
|
239 Acute kidney injury in children |
|
|
2024 | (14) |
|
|
|
240 Acute kidney injury in the elderly |
|
|
2038 | (9) |
|
|
|
|
241 Acute kidney injury in the tropics |
|
|
2047 | (12) |
|
|
242 Acute kidney injury and hantavirus disease |
|
|
2059 | (8) |
|
|
243 Community-acquired pneumonia and acute kidney injury |
|
|
2067 | (1) |
|
|
244 Acute kidney injury in severe sepsis |
|
|
2068 | (8) |
|
|
|
245 Cardiovascular surgery and acute kidney injury |
|
|
2076 | (8) |
|
|
|
246 Contrast-induced acute kidney injury |
|
|
2084 | (7) |
|
|
|
|
|
247 Renal failure in cirrhosis: pathogenesis, diagnosis, and treatment |
|
|
2091 | (18) |
|
|
|
|
248 Acute kidney injury in heart failure |
|
|
2109 | (6) |
|
|
|
|
249 Acute kidney injury in pulmonary diseases |
|
|
2115 | (14) |
|
|
|
250 Acute kidney injury in pregnancy |
|
|
2129 | (4) |
|
|
|
251 Acute kidney injury in the cancer patient |
|
|
2133 | (10) |
|
|
|
|
252 Acute kidney injury in polytrauma and rhabdomyolysis |
|
|
2143 | (8) |
|
|
|
253 Acute kidney injury in patients with severe burn injury |
|
|
2151 | (10) |
|
|
|
|
|
|
|
SECTION 12 The patient on dialysis |
|
|
|
254 Uraemic toxins: overview |
|
|
2161 | (12) |
|
|
|
|
|
|
255 Haemodialysis: overview |
|
|
2173 | (3) |
|
|
256 Haemodialysis: vascular access |
|
|
2176 | (12) |
|
|
257 Haemodialysis: principles |
|
|
2188 | (11) |
|
|
|
258 Haemodialysis: prescription and assessment of adequacy |
|
|
2199 | (19) |
|
|
|
259 Haemodialysis: acute complications |
|
|
2218 | (11) |
|
|
|
260 Haemohitration and haemodiafiltration |
|
|
2229 | (9) |
|
|
|
|
|
261 Dialysis withdrawal and palliative care |
|
|
2238 | (7) |
|
|
|
|
262 Frequent haemodialysis |
|
|
2245 | (15) |
|
|
|
263 Peritoneal dialysis: overview |
|
|
2260 | (3) |
|
|
|
264 Peritoneal dialysis: principles and peritoneal physiology |
|
|
2263 | (11) |
|
|
|
|
265 Peritoneal dialysis: adequacy and prescription management |
|
|
2274 | (7) |
|
|
266 Peritoneal dialysis: non-infectious complications |
|
|
2281 | (9) |
|
|
|
267 Overview of dialysis patient management and future directions |
|
|
2290 | (6) |
|
|
|
|
268 Cardiovascular complications in end-stage renal disease patients: pathophysiological aspects |
|
|
2296 | (8) |
|
|
269 Bacterial and fungal infections in patients on haemodialysis |
|
|
2304 | (6) |
|
|
|
|
270 Bacterial and fungal infections in patients on peritoneal dialysis |
|
|
2310 | (4) |
|
|
|
|
271 Viral infections in patients on dialysis |
|
|
2314 | (2) |
|
|
|
|
272 Cognitive function, depression, and psychosocial adaptation |
|
|
2316 | (8) |
|
|
|
|
273 Volume assessment and management in dialysis |
|
|
2324 | (10) |
|
|
274 Nutritional screening and nutritional management in dialysis patients |
|
|
2334 | (11) |
|
|
|
|
|
SECTION 13 The transplant patient |
|
|
|
275 The evolution of kidney transplantation |
|
|
2345 | (13) |
|
|
|
276 Pre-transplant assessment of the recipient |
|
|
2358 | (8) |
|
|
|
2366 | (12) |
|
|
278 Donor and recipient kidney transplantation surgery |
|
|
2378 | (12) |
|
|
|
279 Immunology, sensitization, and histocompatibility |
|
|
2390 | (15) |
|
|
|
|
|
280 Immediate post-transplant care and surgical complications |
|
|
2405 | (8) |
|
|
|
281 Immunosuppression: drugs and protocols |
|
|
2413 | (13) |
|
|
|
282 Renal transplant imaging |
|
|
2426 | (15) |
|
|
|
|
2441 | (12) |
|
|
|
284 Infection: prophylaxis, diagnosis, and management |
|
|
2453 | (10) |
|
|
285 Cardiovascular disease: prophylaxis, diagnosis, and management |
|
|
2463 | (8) |
|
|
|
|
|
286 Chronic allograft dysfunction |
|
|
2471 | (12) |
|
|
|
|
287 Cancer after kidney transplantation |
|
|
2483 | (8) |
|
|
|
288 Metabolic bone disease after renal transplantation |
|
|
2491 | (11) |
|
|
289 Recurrent renal disease: prophylaxis, diagnosis, and management |
|
|
2502 | (7) |
|
|
|
290 Paediatric renal transplantation |
|
|
2509 | (12) |
|
|
|
SECTION 14 Renal disease at different stages of life (infancy, adolescence, pregnancy, old age) |
|
|
|
291 Growth and development |
|
|
2521 | (6) |
|
|
292 The adolescent with renal disease: transition to adult services |
|
|
2527 | (3) |
|
|
293 Contraception in patients with kidney disease |
|
|
2530 | (7) |
|
|
|
294 Pregnancy and renal physiology |
|
|
2537 | (12) |
|
|
|
295 Pregnancy in patients with chronic kidney disease and on dialysis |
|
|
2549 | (7) |
|
|
|
296 Pre-eclampsia and related disorders |
|
|
2556 | (10) |
|
|
|
297 Acute kidney injury in pregnancy |
|
|
2566 | (4) |
|
|
|
298 Specific renal conditions in pregnancy |
|
|
2570 | (7) |
|
|
|
299 Pregnancy after renal transplantation |
|
|
2577 | (3) |
|
|
|
300 The kidney in ageing: biology, anatomy, physiology, and clinical relevance |
|
|
2580 | (11) |
|
|
|
SECTION 15 The patient with genetic renal disease |
|
|
|
301 Ethical aspects of genetic testing |
|
|
2591 | (3) |
|
|
302 Antenatal diagnosis and pre-implantation genetic testing |
|
|
2594 | (3) |
|
|
303 The molecular basis of ciliopathies and cyst formation |
|
|
2597 | (20) |
|
|
|
304 The adult with renal cysts |
|
|
2617 | (4) |
|
|
|
305 The child with renal cysts |
|
|
2621 | (4) |
|
|
|
|
|
306 Autosomal dominant polycystic kidney disease: overview |
|
|
2625 | (2) |
|
|
|
307 Autosomal dominant polycystic kidney disease: clinical features |
|
|
2627 | (7) |
|
|
|
308 Autosomal dominant polycystic kidney disease: diagnosis |
|
|
2634 | (4) |
|
|
309 Autosomal dominant polycystic kidney disease: management |
|
|
2638 | (9) |
|
|
|
310 Management of intracranial aneurysms |
|
|
2647 | (2) |
|
|
|
311 Management of cystic liver disease |
|
|
2649 | (4) |
|
|
|
312 Autosomal dominant polycystic kidney disease in children and young adults |
|
|
2653 | (3) |
|
|
|
313 Autosomal recessive polycystic kidney disease |
|
|
2656 | (9) |
|
|
|
314 Bardet--Biedl syndrome and other ciliopathies |
|
|
2665 | (6) |
|
|
|
315 Hepatocyte nuclear factor-1B |
|
|
2671 | (3) |
|
|
316 Nephronophthisis and medullary cystic kidney disease: overview |
|
|
2674 | (3) |
|
|
|
2677 | (5) |
|
|
|
318 Autosomal dominant interstitial kidney disease including medullary cystic disease |
|
|
2682 | (3) |
|
|
319 Oral-facial-digital type 1 syndrome |
|
|
2685 | (3) |
|
|
320 The molecular basis of glomerular basement membrane disorders |
|
|
2688 | (7) |
|
|
|
321 Alport syndrome: overview |
|
|
2695 | (2) |
|
|
|
|
322 Alport syndrome: clinical features |
|
|
2697 | (3) |
|
|
|
|
323 Alport syndrome: diagnosis |
|
|
2700 | (6) |
|
|
|
|
324 Alport syndrome: management |
|
|
2706 | (3) |
|
|
|
|
325 Thin glomerular basement membrane nephropathy and other collagenopathies |
|
|
2709 | (2) |
|
|
|
|
326 Nail patella syndrome |
|
|
2711 | (3) |
|
|
|
327 Molecular basis of nephrotic syndrome |
|
|
2714 | (8) |
|
|
|
328 Molecular basis of renal tumour syndromes |
|
|
2722 | (5) |
|
|
|
329 WT1 and its disorders |
|
|
2727 | (5) |
|
|
|
330 Tuberous sclerosis complex renal disease |
|
|
2732 | (7) |
|
|
|
|
331 Hypoxia-inducible factor and renal disorders |
|
|
2739 | (4) |
|
|
|
332 Von Hippel--Lindau disease |
|
|
2743 | (4) |
|
|
|
333 Molecular basis of complement-mediated renal disease |
|
|
2747 | (10) |
|
|
|
|
334 Inherited metabolic diseases and the kidney |
|
|
2757 | (10) |
|
|
|
335 Fabry disease: overview and pathophysiology |
|
|
2767 | (3) |
|
|
336 Fabry disease: clinical features |
|
|
2770 | (6) |
|
|
337 Fabry disease: diagnosis |
|
|
2776 | (4) |
|
|
338 Fabry disease: management and outcome |
|
|
2780 | (9) |
|
|
|
2789 | (9) |
|
|
|
340 Mitochondrial diseases and the kidney |
|
|
2798 | (10) |
|
|
|
341 APOL1 and renal disease |
|
|
2808 | (3) |
|
|
|
|
342 MYH9 and renal disease |
|
|
2811 | (4) |
|
|
|
SECTION 16 The patient with structural and congenital abnormalities |
|
|
|
343 Human kidney development |
|
|
2815 | (7) |
|
|
|
2822 | (6) |
|
|
|
345 Anatomical types of congenital anomalies: overview of obstruction |
|
|
2828 | (2) |
|
|
|
2830 | (1) |
|
|
|
2831 | (1) |
|
|
|
2832 | (1) |
|
|
349 Normal variation in nephron numbers |
|
|
2833 | (2) |
|
|
350 Renal tubular dysgenesis |
|
|
2835 | (1) |
|
|
351 Congenital solitary functioning kidney |
|
|
2836 | (2) |
|
|
352 Duplex, ectopic, and horseshoe kidneys |
|
|
2838 | (2) |
|
|
353 Pelviureteric junction obstruction and megaureter in children |
|
|
2840 | (2) |
|
|
354 Posterior urethral valves |
|
|
2842 | (2) |
|
|
355 Primary vesicoureteric reflux and reflux nephropathy |
|
|
2844 | (10) |
|
|
356 The patient with urinary tract obstruction |
|
|
2854 | (7) |
|
|
Katherine Bennett-Richards |
|
|
|
357 Retroperitoneal fibrosis |
|
|
2861 | (4) |
|
|
Katherine Bennett-Richards |
|
|
|
358 Branchio-oto-renal syndrome |
|
|
2865 | (2) |
|
|
|
359 Townes-Brocks syndrome |
|
|
2867 | (2) |
|
|
|
360 Renal coloboma syndrome |
|
|
2869 | (2) |
|
|
|
361 Ante- and postnatal imaging to diagnose human kidney malformations |
|
|
2871 | (14) |
|
|
|
|
|
SECTION 17 Drugs and renal disease |
|
|
|
362 Drug-induced nephropathies |
|
|
2885 | (26) |
|
|
|
363 Drug dosing in chronic kidney disease |
|
|
2911 | (8) |
|
|
|
|
364 Drug dosing in acute kidney injury |
|
|
2919 | |
|
|
|
|
SECTION 18 Nephrology in the future |
|
|
|
365 A global curriculum for training the next generation of nephrologists |
|
|
|
|
|
Index |
|